cisplatin,pemetrexed,pembrolizumab,gemcitabine
merck
['key,note,62', 'keynote,671', 'lung', 'pembro', 'keynote-671']
presented at #asco23: in the keynote-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. two-year event-free survival was 62.4% with pembrolizumab &amp; 40.6% with placebo.
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.